Press Releases April 28, 2026 03:24 PM

Medallion Financial Corp. to Report 2026 First Quarter Results on Wednesday, April 29, 2026

Medallion Financial Corp. Schedules Q1 2026 Earnings Release and Conference Call

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
MFIN

Medallion Financial Corp., a specialty finance company serving various consumer and commercial sectors, announced it will report its first quarter 2026 financial results after market close on April 29, 2026, followed by an earnings call on April 30, 2026.

Medallion Financial Corp. to Report 2026 First Quarter Results on Wednesday, April 29, 2026
MFIN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Medallion Financial Corp. originates and services consumer and mezzanine loans across several industries including recreation and home improvement.
  • The company partners with fintech firms to offer additional loan products and services, reflecting integration with financial technology.
  • Earnings release scheduled after market close with a follow-up conference call and webcast for investors and analysts.

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Medallion Financial Corp. (NASDAQ: MFIN, the “Company”), a specialty finance company that originates and services loans in various consumer and commercial industries, as well as loan products and services offered through fintech strategic partners, announced today that it will report its results for the quarter ended March 31, 2026, after the market closes on Wednesday, April 29, 2026.

Live Conference Call and Webcast

A conference call to discuss these financial results will be held as follows:

  • Date: Thursday, April 30, 2026
  • Time: 9:00 a.m. ET
  • Dial-in number: (201) 689-8471
  • Live webcast: Link to webcast of 1Q26 Earnings Call

A link to the live audio webcast of the conference call will also be available at the Company’s IR website.

Replay Information

The conference call replay will be available following the end of the call through Thursday, May 7, 2026.

  • Dial-in number: (412) 317-6671
  • Passcode: 13759966

Additionally, the webcast replay will be available at the Company's IR website.

About Medallion Financial Corp.

Medallion Financial Corp. (NASDAQ: MFIN) and its subsidiaries originate and service a growing portfolio of consumer loans and mezzanine loans in various industries, and loan products and services offered through fintech strategic partners. Key industries served include recreation (towable RVs and marine) and home improvement (replacement roofs, swimming pools, and windows). Medallion Financial Corp. is headquartered in New York City, NY, and its largest subsidiary, Medallion Bank, is headquartered in Salt Lake City, Utah. For more information, please visit www.medallion.com.

Contacts:

Medallion Financial Corp.
212-328-2176
[email protected]

Investor Relations
The Equity Group Inc.
Lena Cati
[email protected]
(212) 836-9611

Val Ferraro
[email protected]
(212) 836-9633


Risks

  • Earnings could miss market expectations, leading to potential stock price volatility in the specialty finance sector.
  • Dependence on loan performance in recreational and home improvement industries may expose the company to sector-specific economic fluctuations.
  • Regulatory changes affecting loan origination and fintech partnerships could impact business operations and financial results.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026